Introduction {#sec1-1}
============

Alopecia areata (AA) is a chronic inflammatory disorder, characterized by a T-cell autoimmune-mediated attack on the hair follicle, and occasionally on the nails. This leads to patches of non-scarring alopecia on the patient\'s scalp, face, and other hair-bearing skin of the body. The reported lifetime risk of developing AA has been estimated to be 1.7% and accounts for up to 2% of new cases in a dermatology clinic in the West.\[[@ref1]\]

Pediatric Alopecia Areata {#sec1-2}
=========================

Pediatric alopecia areata is not uncommon. Up to one-third of newly diagnosed AA cases have been reported in patients aged 20 years and below, in both Singapore\[[@ref2]\] and India.\[[@ref3]\] The majority of pediatric AA patients present with localized mild disease affecting less than 50% of the scalp.\[[@ref2]--[@ref5]\] Pediatric AA has been associated with atopy, nail changes, including the twenty nail dystrophy syndrome and a positive family history. In some studies, pediatric AA has also been associated with a guarded long term prognosis, with patients having multiple relapses and progression to alopecia totalis (AT) or universalis (AU).\[[@ref6][@ref7]\]

Up to 50% of AA patients have spontaneous regrowth of their hair within a year without treatment,\[[@ref8]\] thus making watchful waiting a reasonable option for young children with limited disease. For patients with more extensive or progressive disease, it would be important to discuss with the parents the various treatment options available, bearing in mind the child\'s ability to accept and tolerate more invasive procedures.

Treatment Options in Pediatric Alopecia Areata {#sec1-3}
==============================================

A Cochrane Review of AA treatments in 2008 concluded that there is a paucity of well-designed randomized trials to guide treatment.\[[@ref9]\] Evaluation of efficacy is also difficult in AA where spontaneous remission is common, and great disease heterogeneity exists. Significantly, there are even fewer studies on childhood AA and hence, much of the evidence pediatric is extrapolated from adult AA data. Long-term safety data is also less well-established in children, for example with the use of topical immunotherapy.

Management of pediatric AA is particularly challenging given the chronicity of the condition. It is crucial to evaluate the impact of the disease on the child\'s physical and emotional well-being, including issues like self-confidence, self-image, and acceptance by peers. Parental anxiety, frustration, guilt, and expectations must also be proactively managed to ensure an overall holistic management of the patient.

We review the various established treatments, as well as off label and new therapies for AA below.

Treatment options with strength of recommendation B {#sec2-1}
---------------------------------------------------

### Topical corticosteroids (Quality of evidence III) {#sec3-1}

Local application of potent topical corticosteroids has been effective in the treatment of moderate-to-severe AA. A 12-week half-head study of 0.05% clobetasol propionate foam against placebo showed regrowth of at least 50% in 7/34 treated sites compared with 1/34 of the placebo-treated sites.\[[@ref10]\] In patients with AT/AU, 29% (8/27) responded to 0.05% clobetasol propionate ointment under occlusion.\[[@ref11]\]

In our center, topical steroid therapy is the first-line treatment for pediatric cases of AA, given its ease of use, convenience, and lack of pain. We advocate using a highly potent topical corticosteroid such as 0.05% clobetasol propionate lotion, and subsequently, tailing down to a lower potency corticosteroid, such as 0.1% mometasone furoate or 0.1% betamethasone valerate scalp lotion to avoid skin atrophy.

### Topical minoxidil (Quality of evidence III) {#sec3-2}

Minoxidil (2, 4 dinitro-6-piperidinopyrimidine-3-oxide) is an established topical treatment for non-scarring alopecia such as AA. One study showed 3% minoxidil under occlusion led to more regrowth in extensive AA when compared to placebo.\[[@ref12]\] In another study, comparing minoxidil at concentrations of 1% and 5% for extensive AA, patients receiving 5% minoxidil experienced more regrowth.\[[@ref13]\] Both these studies included children, although no subgroup analysis was done for pediatric cases. In the latter study, Price included an anecdotal report of a 9-year-old girl with 100% regrowth after 48 months of monotherapy with minoxidil.\[[@ref13]\] Since minoxidil is unlikely to have any immunomodulatory effect on the autoimmune attack of the hair follicle,\[[@ref14]\] it likely acts synergistically with corticosteroids\[[@ref15]\] to improve outcomes in AA.

In our center, topical 2% or 5% minoxidil is used as an adjunctive treatment, in combination with topical or intralesional steroids. Hypertrichosis on the face and neck may be more common in children, especially at higher concentrations. As such, 2% topical minoxidil may be preferred in children. Topical minoxidil may also cause irritant contact dermatitis or aggravate pre-existing seborrheic or atopic dermatitis. Serious systemic, but non-fatal, side effects such as hypotension and tachycardia were reported in a young girl who ingested 100 ml of minoxidil hair lotion.\[[@ref16]\] As such, parents should be counseled to keep the medicines out of reach of children.

### Intralesional corticosteroids (Quality of evidence III) {#sec3-3}

Injection of corticosteroids into the deep dermis and upper subcutis of the affected areas is the treatment of choice for localized AA in adults, achieving adequate tissue concentrations with minimal systemic absorption.\[[@ref17]\] It has been shown to be effective in several uncontrolled trials,\[[@ref18]--[@ref20]\] including a Singapore study that reported a significant improvement in up to 82% of patients with limited AA treated with monthly intralesional triamcinolone acetonide for 12 weeks.\[[@ref21]\]

For scalp lesions, we use triamcinolone acetonide 10 mg/ml, injecting 0.05-0.1 ml per site, spaced 1 centimeter apart. Triamcinolone acetonide should be diluted to 2.5-5 mg/ml for the eyebrows and face. Side effects include pain, skin depressions secondary to localized atrophy, and hypopigmentation. Peri-orbital injections may be associated with complications such as glaucoma, cataracts, and retinal vascular occlusion.

Usage of intralesional corticosteroids is limited in children due to the fear of injections and pain. Some options to reduce pain include the use of smaller gauge 30 G or 32 G needles, ice or cold compresses, ethyl chloride spray, distraction therapy, and the application of topical anesthetic creams. The use of topical anesthetic creams such as EMLA (eutectic mixture of local anesthetics containing lidocaine 2.5% and prilocaine 2.5%) is an important way to decrease pain and increase patient acceptance. The maximum dose and surface area of EMLA that can be used safely in children varies according to age and can be found in Annex 2. Potential side effects of EMLA would be local irritation and rarely methaemoglobinaemia due to systemic absorption of prilocaine, especially in neonates and very young children.\[[@ref22][@ref23]\] An alternative is ELA-Max cream, which is prilocaine-free, which has a similar efficacy to EMLA cream and a good safety profile in children.\[[@ref24]\]

### Topical immunotherapy (Quality of evidence IIb) {#sec3-4}

Topical immunotherapy is indicated for chronic and extensive AA where prolonged topical or intralesional corticosteroid injections are impractical or ineffective. It has been shown to modulate the local autoimmune attack on the hair follicles,\[[@ref25]\] with reported response rates ranging from 9% to 87% in adult patients. Response rates have been found to be comparable in the pediatric AA, with about one-third of patients experiencing regrowth.\[[@ref26][@ref27]\] Relapse rates in pediatric studies varies from 25% to 90%,\[[@ref28]\] with cases having more extensive disease having a poorer prognosis. In our local series of Singaporean AA patients, those aged between 4 and 20 years were found to have a poorer response to topical immunotherapy.\[[@ref21]\]

Contact sensitizers used today include diphenylcyclopropenone (DPCP) and squalene acid dibutyl ester (SADBE). The original sensitizer dintrochlorobenzene (DCNB) is no longer in use as it has been found to be potentially mutagenic in the Ames test. SADBE is a strong sensitizer but is not stable in acetone and undergoes hydrolysis in storage frequently. Hence, we favor the use of DPCP, with a protocol described by Happle *et al*.\[[@ref29]\] The patient is first sensitized with 2% DPCP on a 2 centimeter bald patch on the scalp. This is left on for 24 hours and washed off. Patients are reviewed 2 weeks later. Sensitization to DPCP is successful if an eczematous reaction is noted over that patch. Subsequently, DPCP, starting at 0.0001% concentration, is applied weekly at increasing concentrations with a goal to induce a mild eczematous reaction and a tolerable itch that lasts 1-2 days. The DPCP is left on for 24 hours each time and washed off. As DPCP is degraded by light, patients are advised to shield the treated areas from light for 24 hours after application.

While topical immunotherapy has been used since 1983, with no serious long-term sequelae has been reported to date,\[[@ref30][@ref31]\] parents and patients should be counseled carefully regarding the common side effects of topical immunotherapy, especially irritant contact dermatitis. In severe cases, patients may have generalized eczema, regional lymphadenopathy, or urticaria. Children with atopic dermatitis or seborrheic dermatitis may be at higher risk of such side effects. Other reported cutaneous side effects include hyperpigmentation and hypopigmentation, including vitiligo. DPCP is highly sensitizing and should be applied by trained medical or nursing personnel who must be protected to avoid sensitization. Adequate precautions should be taken by family members as well.

### Pulsed Systemic Corticosteroids (Quality of evidence Ib) {#sec3-5}

Pulsed systemic corticosteroid therapy is a treatment option aimed at arresting the underlying inflammatory process while attempting to avoid its long-term side effects.\[[@ref32]\] Most clinical trials studying this treatment option are uncontrolled, or adopt different dosing protocols, making comparison and meta-analysis difficult.\[[@ref33][@ref34]\] Pulse intravenous methylprednisolone has been found to be beneficial in several studies,\[[@ref35][@ref36]\] but significant risks such as hypokalemia and cardiac arrhythmias necessitate careful patient monitoring. In children with extensive patchy AA or AT/AU, high dose pulse methylprednisolone was shown to have a poor long-term outcome, with 66% of patients having less than 30% regrowth after a median of 12 months.\[[@ref37]\] No adverse effects were noted in this small case series.

Pulsed oral corticosteroids for AA have also been shown to be effective in children without significant side effects.\[[@ref34][@ref38]\] The dose tested in an uncontrolled case series of 16 young patients was equivalent to oral prednisolone 5 mg/kg/month for 3 months in patients aged 3-11 years and 300 mg/month for 3 months in patients aged 12-18 years. All patients had either extensive AA or AT, and 60% experienced excellent results, even 3 months after the end of the treatment period. The side effects reported were mild epigastric burning and transient giddiness or headache in 2 patients.

Treatment options with strength of recommendation C {#sec2-3}
---------------------------------------------------

### Systemic corticosteroids (Quality of evidence III) {#sec3-6}

Although there are no trials examining the effects of daily systemic corticosteroids in children, it has been shown to be able to induce regrowth in adult AA.\[[@ref39]\] However, the well-known adverse effects of long-term corticosteroid therapy, particularly growth retardation, metabolic dysregulation and reduced bone mineral density, limits its use in children. Hence, it is reserved for patients with rapid onset or rapidly progressive extensive, active AA. Oral prednisolone 0.5 mg-0.8 mg/kg/day is prescribed, and slowly tapered over 2 months, and not exceeding 3 months.

### Dithranol (Quality of evidence IV) {#sec3-7}

Topical dithranol has been reported to be mildly effective in several small studies\[[@ref40][@ref41]\] and has been postulated to act by suppressing the local Th1 immune reaction at the hair follicle. It is available in 0.2% to 0.5% cream or ointment base and needs to be used for at least 3 months for clinical effect. Contact dermatitis is common, and it can stain the patient\'s clothes. It may be useful in children who have failed first- or second-line therapies.

### Phototherapy (Quality of evidence IIb) {#sec3-8}

Topical PUVA is a widely used modality with reported success rates of 50-70%.\[[@ref42][@ref43]\] However, most studies were uncontrolled, and a retrospective analysis suggest that is may be no better than the natural course of AA,\[[@ref44]\] except for the beard area.\[[@ref45]\] Like dithranol, it may have a role when combined with corticosteroids for extensive AA.\[[@ref46]\] In recalcitrant cases of adult AA, combination therapy with oral prednisolone at 20 mg/day and twice-weekly oral PUVA resulted in good regrowth of terminal hairs for some patients. No equivalent studies have been conducted in children, but due to uncertain response rates and potential side effects from cumulative UVA radiation including photo-aging, eye damage, and increased skin cancer risk, PUVA should only be considered as third- or fourth-line treatment. Narrow-band UVB (NBUVB) therapy has not been shown to be effective in extensive AA. Only 20% of patients achieved excellent responses with NBUVB in a recent uncontrolled study, but these patients also received systemic corticosteroids concurrently.\[[@ref47]\] To our knowledge, there have been no reports on the efficacy of UVA1 therapy on childhood AA.

### Laser therapy (Quality of evidence III) {#sec3-9}

The 308-nm Excimer laser showed some efficacy in treating AA in several small case series, mainly as an adjuvant treatment in recalcitrant cases.\[[@ref48][@ref49]\] There has been a case report of the use of fractional photothermolysis laser to effectively treat AA in a patient who previously failed topical minoxidil, topical steroids, and intralesional steroid injections.\[[@ref50]\]

### Immunosuppressive agents (Quality of evidence III) {#sec3-10}

Corticosteroid-sparing immunosuppressive agents such as methotrexate, azathioprine, and cyclosporine have been reported in several cases series to be effective in AA.

Methotrexate has been reported to produce 64% recovery when used together with daily oral prednisolone for adult patients with AT/AU.\[[@ref51]\] A retrospective uncontrolled study of children with severe AA treated with methotrexate for a mean of 14.2 months had only 38.4% response.\[[@ref52]\]

A pilot study of 20 patients (age range 8-57) treated with azathioprine 2 mg/kg/day showed a significant regrowth of 52.3% after a mean of 3 months.\[[@ref53]\] Cyclosporine has been postulated to be an ideal drug for the treatment of AA due to its ability to suppress T-helper cells, suppress interferon-gamma (IFN-γ) production, with an additional side effect of hypertrichosis. Reported efficacy of oral cyclosporine range from 25% when combined with low-dose oral prednisolone\[[@ref54]\] to 88.4% when combined with weekly pulsed methylprednisolone.\[[@ref55]\] In general, use of these agents is limited in children because they require frequent blood tests to monitor for potential side effects.

### Topical calcineurin inhibitors (Quality of evidence Ib) {#sec3-11}

Topical calcineurin inhibitors (TCIs) have been used in pediatric inflammatory conditions such as atopic dermatitis, psoriasis, and vitiligo with success.\[[@ref56]\] The main advantage of TCIs lie in their steroid-sparing effects and may be an option for facial or eyebrow involvement in young children. However, studies supporting their efficacy are lacking. A recent randomized trial comparing intralesional corticosteroids, topical corticosteroids, and TCIs in 78 adult patients with localized AA showed topical tacrolimus to be the least efficacious of the three.\[[@ref57]\] Furthermore, one case report reported no response in AA with topical pimecrolimus.\[[@ref58]\]

### Topical retinoids (Quality of evidence IIb) {#sec3-12}

There are limited published studies for topical retinoids in the treatment of AA and none in children. An uncontrolled, non-randomized 3-month trial of 80 patients with limited AA showed a 70% response rate with topical steroids, 55% with topical tretinoin 0.05%, and 20% in controls.\[[@ref59]\] Topical bexarotene, a retinoid X receptor agonist, was studied in single-blinded, half-head study involving 42 patients, which showed some efficacy.\[[@ref60]\]

Treatment options with strength of recommendation D {#sec2-4}
---------------------------------------------------

### Prostaglandin analogues (Quality of evidence Ib) {#sec3-13}

A new and emerging treatment for non-scarring hair loss is the use of prostaglandin F2α analogues, such as latanoprost and bimatoprost, which have been shown to cause eyelash hypertrichosis. It is postulated to work by enhancing conversion of hairs from telogen to anagen stage.\[[@ref61]\] However, topical latanoprost and bimatoprost were both found to be ineffective in stimulating eyelash regrowth in several randomized controlled studies of AA patients with eyelash loss.\[[@ref62][@ref63]\] Although the safety of prostaglandin analogues in the treatment of pediatric glaucoma is well-established,\[[@ref64]\] this novel off-label treatment for AA has not been validated in children.

### Biologics (Quality of evidence IIb) {#sec3-14}

Although tumor necrosis factor (TNF)-α has been found to be significantly elevated in the sera of AA patients,\[[@ref65]\] anti-TNF-α therapies have found to be ineffective in AA.\[[@ref66]--[@ref68]\] As such, biologics cannot be recommended for treatment of AA at this juncture.

Holistic management of pediatric AA patients {#sec2-5}
--------------------------------------------

Management of AA should also include an assessment of the child\'s psychosocial well-being, emotional response, and coping mechanisms to their disease, as well as the expectations of the caregivers. AA has been associated with adjustment disorder, anxiety, and depression in adults and children.\[[@ref69]\] Adolescents are particularly prone to body image disorders due to their need for peer acceptance and establishment of their identity. A small sample of 14 children and adolescent patients with AA found a high rate of depression (50%) and obsessive-compulsive disorder (35.7%).\[[@ref70]\] In addition, both adult and pediatric AA patients have been found to have heightened stress perception, causing them to handle stressful life events less effectively than healthy subjects.\[[@ref71]\] This is important as AA has been reported to be triggered by stressful events in the patient\'s life,\[[@ref68]\] and poor coping mechanisms may perpetuate disease activity.

Patients with significant psychiatric co-morbidities should be co-managed together with a psychiatrist.\[[@ref72]\] Anti-depressants such as paroxetine, a selective serotonin re-uptake inhibitor,\[[@ref73]\] and hypnotherapy\[[@ref74]\] have been shown in small trials to help hair regrowth over placebo in adults.\[[@ref75]\] AA support groups are important resource groups for patients and their caregivers to gain further insight, emotional support, and acceptance of their condition.\[[@ref76]\] We have found that cosmetic camouflage with wigs or "scalp prostheses" have been very helpful in patients and should be proactively discussed.

Conclusions {#sec1-4}
===========

Alopecia areata is a common yet challenging condition to manage in the Pediatric Dermatology clinic. While many patients with localized AA will respond well to first-line treatment with topical or intralesional corticosteroids, some patients will require more aggressive or second-line therapy. Pediatric age of onset, more extensive disease (scalp involvement more than 50%, ophiasis, or AT/AU), and recalcitrance to initial therapies\[[@ref7]\] may highlight patients who will prove to be challenging to manage. Some of these patients may benefit from a cocktail of established therapies, whereby the synergy between two or more established therapies proves to be better than monotherapy.\[[@ref41]\] Future studies focusing on such combination therapies, as well as novel new treatments not mentioned in this review because of lack of evidence (non-TNF-α biologics, drugs directed against nerves like capsaicin, and low-level light therapy devices), will expand the choices available to dermatologists, patients and their parents in the treatment of pediatric AA.

We have included a treatment algorithm for pediatric cases of AA (Annex 3) as a guide, but treatment will need to be individualized and based on discussion with the child and their parents.

Annex 1 {#sec1-5}
=======

Levels of evidence {#sec2-6}
------------------

Ia Evidence obtained from meta-analysis of randomized controlled trials.

Ib Evidence obtained from at least one randomized controlled trial.

IIa Evidence obtained from at least one well-designed controlled study without randomization.

IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.

III Opinions of respected authorities based on clinical experience, descriptive studies or reports of expert committees

IV Evidence inadequate due to problems of methodology (e.g. sample size or length of comprehensiveness of follow-up or conflicts of evidence).

Grades of recommendation {#sec2-7}
------------------------

AThere is good evidence to support the use of the procedureBThere is fair evidence to support the use of the procedureCThere is poor evidence to support the use of the procedureDThere is fair evidence to support the rejection of the use of the procedureEThere is good evidence to support the rejection of the use of the procedure

Annex 2 {#sec1-6}
=======

![](IJD-57-459-g001)

Maximum doses of EMLA according to age, for use on intact skin (From EMLA Online Data Sheet, AstraZeneca, Auckland, NZ).

Annex 3: Summary of Recommendations for Treatment of AA in the Pediatric Age Group {#sec1-7}
==================================================================================

For limited patchy AA {#sec2-8}
---------------------

First-line treatment:

\< 10 years old: Topical steroids +/- topical Minoxidil lotion\>10 years old: Intralesional steroids +/- Minoxidil lotion

Second-line treatment:

Topical immunotherapy (DPCP)

Third-line treatment:

Dithranol

Fourth-line treatment:

Topical PUVA therapyExcimer laser therapyOther miscellaneous treatment

For rapidly progressive, extensive AA {#sec2-9}
-------------------------------------

Oral prednisolone starting at 0.5-0.8 mg/kg/day and tailed off over 2 months+/- topical steroids +/- topical Minoxidil lotionorPulsed systemic corticosteroids

If hair loss still extensive, proceed to treatment for chronic extensive AA

Chronic extensive AA {#sec2-10}
--------------------

First-line treatment:

Topical steroids with topical Minoxidil lotion

Second-line treatment:

Topical immunotherapy (DPCP)

Third-line treatment:

Pulsed systemic corticosteroidsTopical PUVA therapyAzathioprineOther miscellaneous therapies
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